Call Us: +1 424-283-4273

Group 7291

GLP-1 Agonist for Weight Loss

GLP-1 Agonists for Weight Loss - MyConciergeMD

Is it possible to lose weight using GLP-1 agonists? The answer is yes. Wegovy (semaglutide) and Saxendra (liraglutide) are FDA-approved drugs that promote weight loss. To know more about them and how can they support your weight loss journey, visit Hormone Replacement Therapy LA.

What are GLP-1 agonists for weight loss?

GLP-1 agonists mimic the effects of a hormone called glucagon-like peptide 1 (GLP-1), which is naturally produced in the body in response to food consumption.

Only two types of GLP-1 agonists are FDA-approved for chronic weight management in people with overweight or obesity (without type 2 diabetes): Wegovy and Saxenda.

Other GLP-1 agonists, such as Ozempic, are approved for treating type 2 diabetes but may also be prescribed off-label for weight loss in some cases. Interestingly, Ozempic is chemically identical to Wegovy, but it’s packaged and marketed specifically for diabetes treatment.

How do GLP-1 agonists work for weight loss?

GLP-1 agonists function by mimicking the effects of the naturally produced hormone GLP-1.

GLP-1 is involved in:

  • Stimulating insulin release: It helps regulate blood sugar levels.
  • Slowing down gastric emptying: This leads to increased feelings of fullness and reduced appetite.
  • Decreasing food intake: By promoting satiety and reducing cravings.

Benefits of GLP-1 agonists for weight loss

Reduced Appetite and Hunger

By activating receptors involved in appetite regulation, GLP-1 agonists suppress hunger signals and help patients feel satisfied with less food. Patients report decreased drive to eat and reduced cravings throughout the day.

Increased Feelings of Fullness

GLP-1 agonists slow digestion, which promotes satiety after meals. Patients describe feeling full and content faster after starting a meal while taking these medications.

3.5 to 6.5 Pounds of Average Weight Loss

According to a systematic review and meta-analysis of randomized controlled trials published in the British Medical Journal. The study looked at people taking a GLP-1 agonist medication versus people not taking the medication over 12 months. 

On average, the group taking the GLP-1 medication lost 2.3 kg (about 5 pounds) more weight than the comparison group not getting the medication. The researchers are 95% confident that people on the medication lost between 1.6 and 3 kg (3.5 to 6.5 pounds) more than those not on medication [1].

Improved Body Composition

Because of substantial fat loss, weight loss reflects improved body composition – losing fat while retaining or even increasing lean muscle mass through metabolic changes.

Sustainable Results

Appetite regulation and weight effects persist with continued treatment over 1-2 years to achieve long-term weight maintenance.

How it works

Contact us at +1 424-283-4273 to schedule an in office consult or virtual consult

or Book Online to receive your prescription of Wegovy or other Semaglutide or Trizepatide for weight loss.

  • Virtual Consult with MD & Nutritionist $450
  • 3 Month Supply of the best compounded semaglutide injection  $750 ( Special Pricing) 
  • Follow Ups $250
  • Lose 10 – 20% of body fat safely and effectively
David

Are GLP-1 agonists specifically designed for weight loss, or is it an off-label use?

Only two types of GLP-1 agonists, Wegovy and Saxenda, are approved by the Food and Drug Administration (FDA) for chronic weight management for people with overweight or obesity (without type 2 diabetes)1. Other GLP-1 agonists, such as Ozempic, are approved for the treatment of type 2 diabetes but may also be prescribed off-label for weight loss in some cases.

GLP-1 Approved For Weight Loss

Wegovy

Wegovy is an FDA-approved medication for chronic weight management in adults. In 2021, Wegovy received regulatory approval for long-term obesity treatment based on strong clinical trial efficacy and safety data.

In a 2021 research review, the efficacy of taking 2.4 mg of Wegovy weekly in weight reduction was highlighted across multiple studies, proving more effective than a placebo [2].

In separate studies involving 803 and 1,961 obese individuals, those on a 2.4 mg weekly dosage of Wegovy experienced notable reductions in body weight by 7.9% and 14.9%, respectively. Moreover, they showed improvements in waist circumference, HbA1c levels, blood pressure, total cholesterol, and triglycerides [3,4].

In a 2022 study involving 338 participants, Wegovy (semaglutide) was compared with Saxenda (liraglutide) alongside diet and exercise modifications. Over 68 weeks, Wegovy users exhibited significantly greater weight loss, attributed to reduced cravings and hunger leading to decreased food intake [5].

Compared to the placebo group following the same diet and exercise regimen, Wegovy users either prevented weight gain or exhibited more significant weight loss.

However, it’s crucial to note that the researchers of these studies received funding from Novo Nordisk, the manufacturer of Wegovy, raising potential concerns about bias and conflicts of interest.

Saxenda

Saxenda is an injectable GLP-1 agonist used for weight management in adults and children over 12 with obesity. It is taken daily in conjunction with diet and exercise changes. Saxenda was approved by the FDA for chronic weight management in adults in 2014, also gaining pediatric approval in 2020 based on clinical trial evidence.

In a 2021 study with 169 individuals with obesity, 62.1% experienced a minimum 5% body weight reduction within 6 months using liraglutide. Moreover, about 17.2% of those on liraglutide achieved a significant 10% reduction in body weight [6].

Another 2021 study involving 277 participants revealed that a daily 3 mg dosage of liraglutide led to an average weight loss of 9 pounds (4.1 kilograms) after 7 months, equivalent to about 4.2% of their initial body weight [7].

It’s important to note that the latter study was funded by Novo Nordisk, the manufacturer of Saxenda.

While Saxenda isn’t approved for treating type 2 diabetes, some research suggests it may aid in managing blood sugar levels [8].

Ozempic

Ozempic (semaglutide) is an injectable medication approved to enhance blood sugar control in adults diagnosed with type 2 diabetes. Despite being the same medication as Wegovy, Ozempic is offered in a lower dosage and is not specifically intended for weight loss purposes.

In a 2018 study involving individuals with type 2 diabetes, both high (1 mg weekly) and low (0.5 mg weekly) doses of Ozempic demonstrated greater efficacy compared to Trulicity (dulaglutide), another GLP-1 agonist. These doses effectively improved blood sugar control and led to weight reduction [9].

Similarly, a 2019 study with 577 participants diagnosed with type 2 diabetes compared the effects of Ozempic (1 mg per week) and Victoza (liraglutide), a daily-administered GLP-1 agonist, over 30 weeks. Notably, Ozempic not only proved more efficient in long-term blood sugar management but also resulted in participants losing more than three times the amount of weight [10].

Mounjaro

The FDA recently approved a new GLP-1 agonist medication called Mounjaro (tirzepatide) for adults with type 2 diabetes. This once-weekly injectable drug was designed to help manage blood sugar levels in combination with diet, exercise, and other diabetes treatments. Mounjaro is mainly prescribed for managing blood sugar levels. However, one study suggests that it can facilitate weight loss with proper diet and exercise.

In a 2022 study examining the impact of once-weekly tirzepatide doses (5 mg, 10 mg, and 15 mg) on individuals with obesity or overweight and at least one weight-related condition, results after 72 weeks showed average weight reductions of 15%, 19.5%, and 20.9% for the respective dosage groups [11].

Common Side Effects of GLP-1 Agonists

Common Side Effects of GLP-1 Agonists - MyConciergeMD

  • Nausea and vomiting
  • Headache and fatigue
  • Stomach pain
  • Dizziness
  • Constipation or diarrhea
  • Low blood sugar
  • Mood swings
  • Heartburn 
  • Indigestion
  • GERD (gastroesophageal reflux disease)
  • Bloating
  • Belching or flatulence

What are the costs/coverage?

Costs range from $1000-1500 monthly without insurance. Some plans do cover, often with prior authorization needed. Manufacturer savings cards can provide co-pay assistance for those with coverage.

How long does it take to see weight loss results?

Most patients notice some appetite and eating habit changes within a few weeks. Early weight loss of around 5% may occur in the first 3 months. Maximum results take upwards of 9-12 months for full effects on body weight.

When would GLP-1 treatment stop being effective?

If you develop persistent, severe side effects or fail to respond with at least 5% weight loss in 3-6 months, your prescriber may reassess suitability and explore alternative therapies or interventions.

GLP-1 agonist for weight loss near me

Hormone Replacement Therapy LA offers the best GLP-1 agonist for weight loss near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.

References:

  1. Moore, P.W., Malone, K., VanValkenburg, D. et al. GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. Adv Ther 40, 723–742 (2023). https://doi.org/10.1007/s12325-022-02394-w
  2. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. doi:10.1136/jim-2021-001952
  3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
  4. Wilding J, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021;384(11):989-1002. doi:https://doi.org/10.1056/nejmoa2032183
  5. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
  6. Park JS, Kwon J, Choi HJ, Lee C. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine (Baltimore). 2021;100(2):e23780. doi:10.1097/MD.0000000000023780
  7. Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U. Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. Obes Facts. 2021;14(5):568-576. doi:10.1159/000518325
  8. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. doi:10.1002/osp4.84
  9. Pratley RE, Aroda VR, Ildiko Lingvay, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018;6(4):275-286. doi:https://doi.org/10.1016/s2213-8587(18)30024-x
  10. Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17. PMID: 31539622.
  11. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.

Start your hormone replacement program today and become your best self

See other symptom

We help startups in facilitating the development of disruptive te

Can I Take Vitamin B12 And Levothyroxine Together

Can I Take Vitamin B12 And Levothyroxine Together

If you’re managing thyroid issues with levothyroxine and wondering about adding vitamin B12 to your regimen, you’re not alone. Patients often seek to optimize their

Testosterone Supplements for Men: Worthy or Worrysome?

Testosterone Supplements for Men: Worthy or Worrysome?

The world of testosterone supplements for men is flooded with promises of increased energy, muscle growth, and renewed libido. But behind the flashy marketing, it’s

Where To Get Testosterone? The Role of Hormone Replacement Clinics

Where To Get Testosterone? The Role of Hormone Replacement Clinics

Starting the search for testosterone therapy can feel like stepping into uncharted territory. Where do you even begin? Enter the Hormone Replacement Clinics, your guides